In clinical trials, a placebo is a treatment with no active ingredient (e.g., a sugar pill). Why is including a placebo group important in testing a new drug?
- ATo reduce the cost of manufacturing the active drug.
- BTo ensure that every participant receives some treatment.
- CTo control for the placebo effect, where participants improve simply because they believe they are receiving treatment.Correct
- DTo double the sample size of the study.
Why C is right
The placebo effect occurs when patients experience real improvements in health outcomes simply because they believe they are receiving an effective treatment. Including a placebo group allows researchers to separate the actual drug effect from the placebo effect, by comparing the active treatment group to the placebo group.
Why the other 3 choices miss
- A
- Cost considerations are not the statistical rationale for including a placebo group. The purpose is controlling for the placebo effect.
- B
- In a placebo-controlled study, the placebo group receives an inactive substance, not an actual treatment. The goal is to provide a comparison baseline, not to ensure everyone benefits.
- D
- Including a placebo group increases total sample size but the purpose is not simply size inflation. The scientific purpose is to isolate the drug effect.
In a double-blind randomized clinical trial for a new drug, both 'blinding' elements refer to:
- AThe drug is administered in two doses that neither patients nor doctors know about.
- BTwo separate clinical teams independently analyze the data without communicating.
- CThe patients are unaware of their treatment, and the researchers analyzing data are unaware of treatment assignments.Correct
- DThe control group receives no treatment, and both groups are unaware of their assignment.
Why C is right
In a double-blind trial, two groups are blinded: (1) Subjects/patients do not know whether they receive the treatment or placebo — preventing the placebo effect from biasing results. (2) Researchers and clinicians administering and evaluating treatments do not know which group received which treatment — preventing observer bias. Both forms of bias can distort outcomes in ways that favor the treatment, which is why double-blinding is considered the gold standard for clinical trials.
Why the other 3 choices miss
- A
- Incorrect. 'Double-blind' refers to who is blinded (subjects and researchers), not to the dose structure. Two doses are not part of the definition of a double-blind trial.
- B
- Incorrect. Independent analysis teams are part of some research integrity procedures but are not what 'double-blind' means. Double-blind refers to blinding of subjects and researchers/evaluators, not independent teams.
- D
- Incorrect. A control group receiving no treatment (or a placebo) is a feature of controlled trials in general, not specifically of double-blinding. Double-blinding specifically refers to who is unaware of treatment status.